Skip to content

Released Feb 26, 2025, after the close

10-K filed Mar 11, 2025, 70 days after period end · 0000950170-25-036608

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$890.00Kderived−96.8% vs Q4 2023−96.0% vs Q3 2024
Net Income-$34.07MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$1,805,000N/M
Operating Incomederived-$10,343,000N/M
Operating Cash Flowderived-$14,059,000N/M
Free Cash Flowderived-$17,441,000N/M
Margins · derived
Gross margin-202.8%−250.4 pt vs Q4 2023
Operating margin-1162.1%−1086.3 pt vs Q4 2023
Net margin-3828.3%−3758.2 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$890.00K$28.19M$27.02M$38.27M
Net Income-$34.07M-$19.78M-$20.85M-$9.43M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR